Outcomes in children with idiopathic pulmonary arterial hypertension

Circulation

Volumn 110, Issue 6, 2004, Pages 660-665

  Yung, Delphine ^a   Widlitz, Allison C ^a   Rosenzweig, Erika Berman ^a   Kerstein, Diane ^a   Maislin, Greg ^b   Barst, Robyn J ^a  

^a Columbia Univ Coll of Phys/Surgs ^*  (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Hypertension, pulmonary; Pediatrics; Prostaglandins; Pulmonary heart disease

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; PROSTACYCLIN;

ARTICLE; CHILD; FEMALE; HEMODYNAMICS; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME; VASODILATATION;

ADOLESCENT; ANTICOAGULANTS; CALCIUM CHANNEL BLOCKERS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EPOPROSTENOL; FEMALE; FOLLOW-UP STUDIES; HEART SEPTUM; HEART TRANSPLANTATION; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; INFANT; LIFE TABLES; MALE; MORTALITY; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 4043161231     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000138104.83366.E9     Document Type: Article

References (14)

1. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(suppl):S5-S12.
2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115:343-349.
3. Sandoval J, Bauerle O, Gomez A, et al. Primary pulmonary hypertension in children: clinical characterization and survival. J Am Coll Cardiol. 1995;25:466-474.
4. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
5. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999;99:1197-1208.
6. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med. 1990;112:485-491.
7. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994;121:409-415.
8. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334:296-302.
9. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477-1482.
10. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol. 1997;30:343-349.
11. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780-788.
12. Kuhn KP, Byrne DW, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med. 2002;167:580-586.
13. Sitbon O, Humbert M, Ioos V, et al. Who benefit from long-term calcium-channel blocker (CCB) therapy in primary pulmonary hypertension (PPH)? Am J Respir Crit Care Med. 2003;167:A440. Abstract.
14. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70:580-587.